A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat
Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The study was performed to evaluate the analgesic efficacy, safety, and tolerability of
valdecoxib 20 mg twice daily (BID), valdecoxib 40 mg once daily (QD), and placebo in patients
with moderately to severely painful symptomatic sore throat over a 24-hour period. In
addition, the study was to validate a new scale and criteria for measuring pain in sore
throat and evaluate the effects of selective serotonin reuptake inhibitors and past sore
throat pain on pain score and efficacy of analgesics. The study also examined what type of
medications are commonly used for sore throat and whether this information has relevance to
analgesic efficacy.